Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14456937 | 0.89 | KCNH2 (0.51) | CYP3A4 | |
| SCHEMBL14456945 | 0.89 | CYP3A4 (0.49) | CYP3A4 | |
| SCHEMBL14456946 | 0.86 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL14456902 | 0.86 | CYP3A4 (0.63) | CYP3A4 | |
| SCHEMBL14456905 | 0.84 | CYP3A4 (0.61) | CYP3A4 | |
| SCHEMBL14456935 | 0.83 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL13003599 | 0.83 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL14456948 | 0.82 | ALDH1A1 (0.52) | CYP3A4 | |
| SCHEMBL14456919 | 0.82 | CYP3A4 (0.61) | CYP3A4 | |
| SCHEMBL14456997 | 0.82 | CYP3A4 (0.50) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7238688-B2 | Piperidine compounds | SCHERING CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238688-B2 | Piperidine compounds | SCHERING CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | CYP3A4 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.